ZA200602994B - Use of organic compounds - Google Patents

Use of organic compounds Download PDF

Info

Publication number: ZA200602994B
Authority: ZA; South Africa
Prior art keywords: patients; use according; benazepril; amlodipine; blood pressure
Prior art date: 2003-10-20

Application number

ZA200602994A

Other languages

English (en)

Inventor

Jamerson Ken

Macnab Malcolm

Pitt Bertram

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-20

Filing date

2006-04-11

Publication date

2008-03-26

2006-04-11 Application filed by Novartis Ag filed Critical Novartis Ag

2008-03-26 Publication of ZA200602994B publication Critical patent/ZA200602994B/en

Links

150000002894 organic compounds Chemical class 0.000 title description 2
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 48
206010020772 Hypertension Diseases 0.000 claims description 42
229960004530 benazepril Drugs 0.000 claims description 34
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 30
229960000528 amlodipine Drugs 0.000 claims description 27
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 22
239000005541 ACE inhibitor Substances 0.000 claims description 21
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 21
239000002934 diuretic Substances 0.000 claims description 19
230000001631 hypertensive effect Effects 0.000 claims description 19
230000001882 diuretic effect Effects 0.000 claims description 16
239000003814 drug Substances 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 13
230000002526 effect on cardiovascular system Effects 0.000 claims description 13
229960004067 benazeprilat Drugs 0.000 claims description 9
MADRIHWFJGRSBP-ROUUACIJSA-N benazeprilat Chemical compound C([C@H](N[C@H]1CCC2=CC=CC=C2N(C1=O)CC(=O)O)C(O)=O)CC1=CC=CC=C1 MADRIHWFJGRSBP-ROUUACIJSA-N 0.000 claims description 9
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 7
-1 chlorthsalldone Chemical compound 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 7
229960002003 hydrochlorothiazide Drugs 0.000 claims description 7
238000011260 co-administration Methods 0.000 claims description 6
CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 claims description 5
FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 5
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 5
229960002576 amiloride Drugs 0.000 claims description 5
NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 claims description 5
229960001541 benzthiazide Drugs 0.000 claims description 5
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 5
229960004064 bumetanide Drugs 0.000 claims description 5
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims description 5
229960003199 etacrynic acid Drugs 0.000 claims description 5
229960003883 furosemide Drugs 0.000 claims description 5
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 5
NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims description 5
229960004569 indapamide Drugs 0.000 claims description 5
AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims description 5
229960002817 metolazone Drugs 0.000 claims description 5
229960005483 polythiazide Drugs 0.000 claims description 5
229920000046 polythiazide Polymers 0.000 claims description 5
AGMMTXLNIQSRCG-UHFFFAOYSA-N quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 claims description 5
229960000577 quinethazone Drugs 0.000 claims description 5
230000009467 reduction Effects 0.000 claims description 5
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 5
229960002256 spironolactone Drugs 0.000 claims description 5
229960001288 triamterene Drugs 0.000 claims description 5
CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 claims description 4
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 4
229960003176 cyclothiazide Drugs 0.000 claims description 4
BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 claims description 4
229960003313 hydroflumethiazide Drugs 0.000 claims description 4
DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 claims description 4
229960003739 methyclothiazide Drugs 0.000 claims description 4
229960005461 torasemide Drugs 0.000 claims description 4
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 3
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 3
229960002155 chlorothiazide Drugs 0.000 claims description 3
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 3
229960005156 digoxin Drugs 0.000 claims description 3
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
230000036772 blood pressure Effects 0.000 description 24
238000000034 method Methods 0.000 description 18
229940127291 Calcium channel antagonist Drugs 0.000 description 15
239000000480 calcium channel blocker Substances 0.000 description 15
238000011282 treatment Methods 0.000 description 15
229940080288 lotrel Drugs 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 13
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 10
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
239000002552 dosage form Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 9
230000035488 systolic blood pressure Effects 0.000 description 9
238000004448 titration Methods 0.000 description 9
230000003276 anti-hypertensive effect Effects 0.000 description 8
206010012601 diabetes mellitus Diseases 0.000 description 7
230000035487 diastolic blood pressure Effects 0.000 description 7
208000024172 Cardiovascular disease Diseases 0.000 description 6
230000007211 cardiovascular event Effects 0.000 description 6
VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 5
229960003619 benazepril hydrochloride Drugs 0.000 description 5
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
238000013461 design Methods 0.000 description 4
230000000250 revascularization Effects 0.000 description 4
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
229940125364 angiotensin receptor blocker Drugs 0.000 description 3
229940030600 antihypertensive agent Drugs 0.000 description 3
239000002220 antihypertensive agent Substances 0.000 description 3
239000002876 beta blocker Substances 0.000 description 3
229940097320 beta blocking agent Drugs 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
229940030606 diuretics Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
230000008816 organ damage Effects 0.000 description 3
239000008188 pellet Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 2
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
102000015427 Angiotensins Human genes 0.000 description 2
108010064733 Angiotensins Proteins 0.000 description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
102000003979 Mineralocorticoid Receptors Human genes 0.000 description 2
108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
102100028255 Renin Human genes 0.000 description 2
108090000783 Renin Proteins 0.000 description 2
206010042957 Systolic hypertension Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
229960002478 aldosterone Drugs 0.000 description 2
239000002160 alpha blocker Substances 0.000 description 2
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 2
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 2
229960004005 amlodipine besylate Drugs 0.000 description 2
238000002266 amputation Methods 0.000 description 2
238000002583 angiography Methods 0.000 description 2
229940127088 antihypertensive drug Drugs 0.000 description 2
229960003515 bendroflumethiazide Drugs 0.000 description 2
HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 2
230000008859 change Effects 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
239000002131 composite material Substances 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000013146 percutaneous coronary intervention Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
201000001474 proteinuria Diseases 0.000 description 2
230000029865 regulation of blood pressure Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000009097 single-agent therapy Methods 0.000 description 2
201000009032 substance abuse Diseases 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000003451 thiazide diuretic agent Substances 0.000 description 2
239000005458 thiazide-like diuretic Substances 0.000 description 2
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010001580 Albuminuria Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
206010027525 Microalbuminuria Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
208000004531 Renal Artery Obstruction Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038378 Renal artery stenosis Diseases 0.000 description 1
201000004239 Secondary hypertension Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
229960001523 chlortalidone Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000013170 computed tomography imaging Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
206010019465 hemiparesis Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940080266 lotensin hct Drugs 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
229940125395 oral insulin Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000009295 sperm incapacitation Effects 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
231100000736 substance abuse Toxicity 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
230000000948 sympatholitic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000019270 symptomatic heart failure Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
229960004813 trichlormethiazide Drugs 0.000 description 1
LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)

ZA200602994A 2003-10-20 2006-04-11 Use of organic compounds ZA200602994B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51263403P	2003-10-20	2003-10-20

Publications (1)

Publication Number	Publication Date
ZA200602994B true ZA200602994B (en)	2008-03-26

Family

ID=34465367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200602994A ZA200602994B (en)	2003-10-20	2006-04-11	Use of organic compounds

Country Status (19)

Country	Link
US (2)	US20060233876A1 (fr)
EP (1)	EP1776115A2 (fr)
JP (1)	JP2007511473A (fr)
KR (1)	KR20060120126A (fr)
CN (1)	CN101137367A (fr)
AU (1)	AU2004281541B2 (fr)
BR (1)	BRPI0415530A (fr)
CA (1)	CA2542757A1 (fr)
IL (1)	IL174927A0 (fr)
IS (1)	IS8470A (fr)
MA (1)	MA28108A1 (fr)
MX (1)	MXPA06004369A (fr)
NO (1)	NO20062236L (fr)
RU (1)	RU2006117198A (fr)
SG (1)	SG147456A1 (fr)
TN (1)	TNSN06111A1 (fr)
TW (1)	TW200524591A (fr)
WO (1)	WO2005037278A2 (fr)
ZA (1)	ZA200602994B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10127130B2 (en) *	2005-03-18	2018-11-13	Salesforce.Com	Identifying contributors that explain differences between a data set and a subset of the data set
US9940405B2 (en)	2011-04-05	2018-04-10	Beyondcore Holdings, Llc	Automatically optimizing business process platforms
US8158146B2 (en)	2005-09-28	2012-04-17	Teva Pharmaceutical Industries Ltd.	Stable combinations of amlodipine besylate and benazepril hydrochloride
CN102008708B (zh) *	2009-07-14	2013-02-20	邬林祥	一种治疗高血压含雷米普利的复方制剂
WO2011161223A2 (fr)	2010-06-23	2011-12-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Formes pharmaceutiques à usage oral comprenant de la lercanidipine et de l'énalapril et leurs sels pharmaceutiquement acceptables
US10802687B2 (en)	2011-12-04	2020-10-13	Salesforce.Com, Inc.	Displaying differences between different data sets of a process
US10796232B2 (en)	2011-12-04	2020-10-06	Salesforce.Com, Inc.	Explaining differences between predicted outcomes and actual outcomes of a process
CN102440993B (zh) *	2011-12-08	2013-04-17	扬子江药业集团广州海瑞药业有限公司	一种氨氯地平和贝那普利的药物组合物
RU2014129508A (ru) *	2011-12-21	2016-02-10	Новартис Тиргезундхайт АГ	Новая комбинация
CN102688245A (zh) *	2012-06-11	2012-09-26	北京阜康仁生物制药科技有限公司	一种稳定的氨氯地平与贝那普利药用组合物及其制备方法
JP2014219945A (ja) *	2013-05-10	2014-11-20	富士通株式会社	治験情報出力装置、治験情報出力方法および治験情報出力プログラム
HRP20230267T1 (hr)	2017-01-25	2023-06-09	The George Institute for Global Health	Pripravci za liječenje hipertenzije
US12521380B2 (en)	2017-01-25	2026-01-13	The George Institute for Global Health	Compositions for the treatment of hypertension
US20200111575A1 (en) *	2018-10-04	2020-04-09	Babylon Partners Limited	Producing a multidimensional space data structure to perform survival analysis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6162802A (en) *	1992-03-10	2000-12-19	Papa; Joseph	Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0795327A1 (fr) *	1996-03-13	1997-09-17	Pfizer Inc.	Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
AU2001225816B2 (en) *	2000-12-18	2005-10-13	Novartis Ag	Therapeutic combination of amlodipine and benazepril
TW200306799A (en) *	2002-05-17	2003-12-01	Novartis Ag	Combination of organic compounds

2004
- 2004-10-19 KR KR1020067009736A patent/KR20060120126A/ko not_active Withdrawn
- 2004-10-19 TW TW093131725A patent/TW200524591A/zh unknown
- 2004-10-19 SG SG200807826-3A patent/SG147456A1/en unknown
- 2004-10-19 CA CA002542757A patent/CA2542757A1/fr not_active Abandoned
- 2004-10-19 MX MXPA06004369A patent/MXPA06004369A/es not_active Application Discontinuation
- 2004-10-19 CN CNA2004800381794A patent/CN101137367A/zh active Pending
- 2004-10-19 EP EP04817199A patent/EP1776115A2/fr not_active Ceased
- 2004-10-19 BR BRPI0415530-0A patent/BRPI0415530A/pt not_active IP Right Cessation
- 2004-10-19 JP JP2006536030A patent/JP2007511473A/ja not_active Withdrawn
- 2004-10-19 WO PCT/EP2004/011824 patent/WO2005037278A2/fr not_active Ceased
- 2004-10-19 AU AU2004281541A patent/AU2004281541B2/en not_active Ceased
- 2004-10-19 RU RU2006117198/15A patent/RU2006117198A/ru unknown
- 2004-10-20 US US10/969,700 patent/US20060233876A1/en not_active Abandoned
2006
- 2006-04-11 IL IL174927A patent/IL174927A0/en unknown
- 2006-04-11 ZA ZA200602994A patent/ZA200602994B/en unknown
- 2006-04-19 TN TNP2006000111A patent/TNSN06111A1/en unknown
- 2006-04-25 MA MA28962A patent/MA28108A1/fr unknown
- 2006-05-16 IS IS8470A patent/IS8470A/is unknown
- 2006-05-18 NO NO20062236A patent/NO20062236L/no not_active Application Discontinuation
2007
- 2007-11-29 US US11/867,891 patent/US20080242659A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MA28108A1 (fr)	2006-08-01
CA2542757A1 (fr)	2005-04-28
EP1776115A2 (fr)	2007-04-25
US20080242659A1 (en)	2008-10-02
IL174927A0 (en)	2008-04-13
RU2006117198A (ru)	2007-12-10
US20060233876A1 (en)	2006-10-19
TW200524591A (en)	2005-08-01
CN101137367A (zh)	2008-03-05
KR20060120126A (ko)	2006-11-24
AU2004281541A1 (en)	2005-04-28
BRPI0415530A (pt)	2006-12-26
NO20062236L (no)	2006-07-19
IS8470A (is)	2006-05-16
WO2005037278A2 (fr)	2005-04-28
JP2007511473A (ja)	2007-05-10
SG147456A1 (en)	2008-11-28
WO2005037278A3 (fr)	2007-05-10
AU2004281541B2 (en)	2008-05-01
MXPA06004369A (es)	2006-06-14
TNSN06111A1 (en)	2007-11-15

Publication	Publication Date	Title
Allemann et al.	2008	Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX‐FAST) study
Bang et al.	2003	Lercanidipine: a review of its efficacy in the management of hypertension
Drummond et al.	2007	Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add‐on therapy in patients not responding to amlodipine monotherapy
Wellington et al.	2002	Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension
KR101529541B1 (ko)	2015-06-17	고양이에서 전신성 질환을 치료하기 위한 안지오텐신 ｉｉ 수용체 길항제
US20080242659A1 (en)	2008-10-02	Compositions and methods for reducing cardiovascular morbidity and/or mortality
US9387249B2 (en)	2016-07-12	Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CZ300687B6 (cs)	2009-07-15	Léciva s obsahem ramiprilu k ošetrování kardiovaskulárních príhod
Melian et al.	2002	Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension
JP7402907B2 (ja)	2023-12-21	ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
Zhu et al.	2012	Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension: a multinational, randomized, double-blind, active-controlled trial
CA2257946A1 (fr)	1997-12-31	Composition a base d'enalapril et de losartan
Frampton et al.	2009	Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension
US20250195525A1 (en)	2025-06-19	Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats
Plosker et al.	2008	Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension
Fenton et al.	2003	Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension
Kes et al.	2003	Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine
Maillard et al.	2005	Telmisartan/hydrochlorothiazide: a new fixed dose combination
Basile	2009	Blood pressure responder rates versus goal rates: which metric matters?
Prescott	2004	Recent Advances in the Treatment of Cardiovascular Diseases
EP4574148A1 (fr)	2025-06-25	Combinaison fixe de telmisartan, d'amlodipine et d'indapamide pour le traitement de l'hypertension
Cremonesi et al.	2003	Efficacy and tolerability of delapril plus indapamide versus lisinopril plus hydrochlorothiazide combination treatments in mild to moderate hypertension: A multicenter, randomized clinical study
Forni et al.	2010	Treating high blood pressure: Is reaching the target more important than the means? No, the means are important